Similarly, some forms of cancer such as gastric cancer, lung cancer andT-cell prolymphocytic leukemia that are driven by PTC mutations in tumor suppressor genes includingCDH1, p53 and CDKN1B may also be considered for treatment with an NMD inhibitor (Lehmanet al, 1991; Karamet al, 2008; Metzeleret al, 2011). This evidence concerns the gene TP53 and lung carcinoma.